The Hair Loss Encyclopedia

Search

for
Search:

GlossaryBortezomib

inhibits proteasomes to treat multiple myeloma and lymphoma

Bortezomib, also known by the brand name Velcade, is a medication used primarily to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, thereby causing cancer cells to die. This targeted action helps to control the growth and spread of cancerous cells.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 63 results

Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies

research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies

44 citations , September 2015 in “Annals of Oncology”

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

research Cutis Verticis Gyrata Heralding a Diagnosis of Primary Systemic Amyloidosis in a Patient with Cardioembolic Stroke

1 citations , January 2023 in “Annals of Indian Academy of Neurology”

Recognizing CVG can help diagnose systemic amyloidosis early.

Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects

research Cutaneous Adverse Reactions Linked to Targeted Anticancer Therapies Bortezomib and Lenalidomide for Multiple Myeloma: New Drugs, Old Side Effects

18 citations , May 2013 in “Cutaneous and Ocular Toxicology”

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

Topical Application of Anti-Cancer Drug Bortezomib Stimulates Proliferation of Follicular Cells and Induces Expression of Hair Keratins via GATA-3 Transcription Factor

research Topical Application of Anti-Cancer Drug Bortezomib Stimulates Proliferation of Follicular Cells and Induces Expression of Hair Keratins via GATA-3 Transcription Factor

April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology”

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

Case Report: Two Instances of Drug Eruption Caused by Bortezomib Presenting as Multiple Plaques on the Trunk

research Case Report: Two Instances of Drug Eruption Caused by Bortezomib Presenting as Multiple Plaques on the Trunk

January 2016 in “대한피부과학회지”

Bortezomib chemotherapy can cause temporary skin rashes.

View more "bortezomib" in research →

Community Join

0 / 0 results

— no results